Drug-resistance in human melanoma

International Journal of Cancer

Volumn 93, Issue 5, 2001, Pages 617-622

  Helmbach, Heike ^a   Rossmann, Evelyn ^a   Kern, Monika A ^a   Schadendorf, Dirk ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Caspase; Cytochrome c; DNA repair; Drug resistance; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CASPASE 8; CISPLATIN; CYTOCHROME C; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FAS ANTIGEN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADVANCED CANCER; APOPTOSIS; CANCER RESISTANCE; CELL TRANSPORT; DNA REPAIR; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0035452330     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1378     Document Type: Short Survey

References (65)

1. The current management of cutaneous melanoma
2. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
3. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
4. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma
5. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity
6. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: Modulation of proto-oncogene expression
7. The chemoresistance of human malignant melanoma: An update
8. Biochemistry of multidrug resistance mediated by the multidrug transporter
9. P-glycoprotein expression in primary and metastatic malignant melanoma
10. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance
11. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance
12. Membrane transport proteins associated with drug resistance expressed in human melanoma
13. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells
14. Glutathione-related mechanisms in cellular resistance to anticancer drugs
15. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells
16. Glutathione and related enzymes in tumor progression and metastases of human melanoma
17. Altered DNA topoisomerase II in multidrug resistance
18. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
19. Acquisition of multiple copies of a mutant topoisomerase II alpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines
20. The role of DNA mismatch repair in drug resistance
21. 6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance
22. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide
23. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
24. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
25. Apoptosis and drug response
26. Induction of apoptosis by cancer chemotherapy
27. Apoptosis and cancer drug targeting
28. The central effectors of cell death in the immune system
29. Biochemical pathways of caspase activation during apoptosis
30. Two CD95 (APO-1/Fas) signaling pathways
31. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
32. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
33. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
34. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
35. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
36. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)
37. Mechanisms of p53-induced apoptosis
38. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
39. Ceramide and the induction of apoptosis
40. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
41. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer
42. Drug resistance in ovarian cancer - The role of p53
43. Overexpression and mutations of p53 in metastatic malignant melanomas
44. Chemotherapy-induced apoptosis in melanoma cells in p53 dependent
45. p53-dependent apoptosis in melanoma cells after treatment with camptothecin
46. Ras mutations in human melanoma: A marker of malignant progression
47. Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis
48. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
49. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma
50. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
51. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma
52. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release
53. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
54. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
55. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines
56. Bcl-2 expression in malignant melanoma and its prognostic significance
57. Dysregulation of apoptosis in cancer
58. Bcl-2 antisense therapy chemosensitizes human melanoma in Scid mice
59. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
60. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
61. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
62. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines
63. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs
64. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis